The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Bookmark and Share
Meta-analysis on Trimebutine Maleate Combined with Oryzanol in Treating Irritable Bowel Syndrome
Pages: 1106-1113
Year: Issue:  9
Journal: Chinese Journal of Modern Applied Pharmacy

Keyword:  trimebutine maleateoryzanolirritable bowel syndromemeta-analysis;
Abstract: OBJECTIVE To systematically evaluate the efficacy and safety of trimebutine maleate combined with oryzanol in treating irritable bowel syndrome(IBS). METHODS Randomized controlled trials(RCTs) of trimebutine maleate combined with oryzanol in treating IBS were identified by searching electronic databases including Cochrane Library, Springer Link, CNKI, PubMed, Embase, CBM, Wanfang Data and VIP Database. Two reviewers extracted data independently and assessed literature quality according to the Cochrane Collaboration Risk Assessment Criteria and meta-analysis was conducted by using RevMan 5.3 software. RESULTS A total of 15 RCTs were included, involving 1 338 patients. The results of meta-analysis showed that compared with the control group, trimebutine maleate combined with oryzanol had better clinical efficacy [RR=1.26, 95%CI(1.20, 1.33), P<0.000 01], and improved clinical symptoms, abdominal pain [SMD=-0.94, 95%CI(-1.22, -0.66), P<0.000 01], diarrhea [SMD=-1.33, 95%CI(-1.68, -0.98), P<0.000 01], daily average number of bowel movements [SMD=-1.41, 95%CI(-1.79, -1.03), P<0.000 01], abnormal proportion of stool characteristics [SMD=-2.82, 95%CI(-3.42, -2.22), P<0.000 01)], and reduced adverse reactions [RR=0.40, 95%CI(0.27, 0.60), P<0.000 1] in the treatment of IBS. CONCLUSION Trimebutine maleate combined with oryzanol has better clinical efficacy and lower adverse reactions compared with trimebutine maleate in the treatment of IBS.
Related Articles
No related articles found